SEC Form 4 · accession 0000899243-18-009681
BIODELIVERY SCIENCES INTERNATIONAL INC · BDSI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ernest Robert De Paolantonio
Officer — CFO, Secretary and Treasurer
Period of report
Apr 3, 2018
Accepted (ET)
Apr 6, 2018 · 6:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001103021
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 3, 2018 | A | 1,267 | $0.00 | A | 97,731 | D | |
| Common StockF2 | Apr 3, 2018 | M | 34,391 | $0.00 | A | 132,122 | D | |
| Common StockF3 | Apr 3, 2018 | M | 30,000 | $0.00 | A | 162,122 | D | |
| Common StockF4 | Apr 3, 2018 | M | 31,667 | $0.00 | A | 193,789 | D | |
| Common StockF5 | Apr 3, 2018 | M | 27,075 | $0.00 | A | 220,864 | D | |
| Common StockF7 | Apr 5, 2018 | S | 30,900 | $2.12 | D | 189,864 | D | |
| Common StockF8 | Apr 6, 2018 | S | 33,255 | $2.06 | D | 156,709 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1 | $0.00 | Apr 3, 2018 | A | 1,267 | D | — | Apr 3, 2018 | Common Stock | 1,267 | 0 | D |
| Restricted Stock UnitsF2 | $0.00 | Apr 3, 2018 | M | 34,391 | D | — | Apr 3, 2018 | Common Stock | 34,391 | 0 | D |
| Restricted Stock UnitsF3 | $0.00 | Apr 3, 2018 | M | 30,000 | D | — | Mar 1, 2019 | Common Stock | 30,000 | 30,000 | D |
| Restricted Stock UnitsF4 | $0.00 | Apr 3, 2018 | M | 31,667 | D | — | Feb 6, 2020 | Common Stock | 31,667 | 63,333 | D |
| Restricted Stock UnitsF5 | $0.00 | Apr 3, 2018 | A | 27,075 | D | — | Feb 6, 2020 | Common Stock | 27,075 | 0 | D |
Explanation of responses
- F1The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long-Term Incentive Plan.
- F2The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended (the "EIP"). Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock.
- F3The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs that were granted to the Reporting Person on February 29, 2016, pursuant to a grant under the EIP. The remainder of the RSUs under this grant will vest on March 1, 2019.
- F4The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 6, 2017 under the EIP. The remainder of the RSUs under this grant will vest in equal portions after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020.
- F5The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the performance-based RSUs ("Performance RSUs") granted to the Reporting Person on February 6, 2017 under the EIP subject to certain performance measures. The remainder of the Performance RSUs under this grant will vest, in equal amounts, but subject to certain performance measures, after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020.
- F6The shares of common stock were sold by the Reporting Person upon expiration of a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's additional tax liability upon the vesting of the Reporting Person's RSUs.
- F7On April 5, 2018, the Reporting Person sold an aggregate of 30,900 shares of the Issuer's Common Stock at a weighted average price of $2.12 per share. The highest sale price for the Common Stock was $2.15 per share and the lowest sale price was $2.08 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F8On April 6, 2018, the Reporting Person sold an aggregate of 33,255 shares of the Issuer's Common Stock at a weighted average price of $2.06 per share. The highest sale price for the Common Stock was $2.15 per share and the lowest sale price was $2.00 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.